Year
2023
-
Sanofi to Acquire Provention Bio
-
After $3.4B deal and EU withdrawal, Novartis looks to sell Xiidra: Bloomberg
-
Formology Lab Gets Warning Letter for Lax Identity Testing, Other Lapses
-
Positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint met
-
Amgen to cut 450 jobs in second round of layoffs this year
-
Sarepta slides as FDA about-turn on panel clouds gene therapy approval path
-
FDA Offers Advice on NDAs for Postoperative Local Anesthetics
-
FDA Approves Novartis Treatment Combination for Pediatric Glioma
-
Paxlovid Gets Advisory Panel Support for Full FDA Approval
-
Mayo Clinic cancer expert highlights advancements in treating multiple myeloma